333 related articles for article (PubMed ID: 27881822)
1. Lowered H3K27me3 and DNA hypomethylation define poorly prognostic pediatric posterior fossa ependymomas.
Bayliss J; Mukherjee P; Lu C; Jain SU; Chung C; Martinez D; Sabari B; Margol AS; Panwalkar P; Parolia A; Pekmezci M; McEachin RC; Cieslik M; Tamrazi B; Garcia BA; La Rocca G; Santi M; Lewis PW; Hawkins C; Melnick A; David Allis C; Thompson CB; Chinnaiyan AM; Judkins AR; Venneti S
Sci Transl Med; 2016 Nov; 8(366):366ra161. PubMed ID: 27881822
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical analysis of H3K27me3 demonstrates global reduction in group-A childhood posterior fossa ependymoma and is a powerful predictor of outcome.
Panwalkar P; Clark J; Ramaswamy V; Hawes D; Yang F; Dunham C; Yip S; Hukin J; Sun Y; Schipper MJ; Chavez L; Margol A; Pekmezci M; Chung C; Banda A; Bayliss JM; Curry SJ; Santi M; Rodriguez FJ; Snuderl M; Karajannis MA; Saratsis AM; Horbinski CM; Carret AS; Wilson B; Johnston D; Lafay-Cousin L; Zelcer S; Eisenstat D; Silva M; Scheinemann K; Jabado N; McNeely PD; Kool M; Pfister SM; Taylor MD; Hawkins C; Korshunov A; Judkins AR; Venneti S
Acta Neuropathol; 2017 Nov; 134(5):705-714. PubMed ID: 28733933
[TBL] [Abstract][Full Text] [Related]
3. Is H3K27me3 status really a strong prognostic indicator for pediatric posterior fossa ependymomas? A single surgeon, single center experience.
Tanrıkulu B; Danyeli AE; Özek MM
Childs Nerv Syst; 2020 May; 36(5):941-949. PubMed ID: 32025869
[TBL] [Abstract][Full Text] [Related]
4. EZH2 inhibitory protein (EZHIP/Cxorf67) expression correlates strongly with H3K27me3 loss in posterior fossa ependymomas and is mutually exclusive with H3K27M mutations.
Nambirajan A; Sharma A; Rajeshwari M; Boorgula MT; Doddamani R; Garg A; Suri V; Sarkar C; Sharma MC
Brain Tumor Pathol; 2021 Jan; 38(1):30-40. PubMed ID: 33130928
[TBL] [Abstract][Full Text] [Related]
5. Common molecular features of H3K27M DMGs and PFA ependymomas map to hindbrain developmental pathways.
Pun M; Pratt D; Nano PR; Joshi PK; Jiang L; Englinger B; Rao A; Cieslik M; Chinnaiyan AM; Aldape K; Pfister S; Filbin MG; Bhaduri A; Venneti S
Acta Neuropathol Commun; 2023 Feb; 11(1):25. PubMed ID: 36759899
[TBL] [Abstract][Full Text] [Related]
6. Molecular heterogeneity and CXorf67 alterations in posterior fossa group A (PFA) ependymomas.
Pajtler KW; Wen J; Sill M; Lin T; Orisme W; Tang B; Hübner JM; Ramaswamy V; Jia S; Dalton JD; Haupfear K; Rogers HA; Punchihewa C; Lee R; Easton J; Wu G; Ritzmann TA; Chapman R; Chavez L; Boop FA; Klimo P; Sabin ND; Ogg R; Mack SC; Freibaum BD; Kim HJ; Witt H; Jones DTW; Vo B; Gajjar A; Pounds S; Onar-Thomas A; Roussel MF; Zhang J; Taylor JP; Merchant TE; Grundy R; Tatevossian RG; Taylor MD; Pfister SM; Korshunov A; Kool M; Ellison DW
Acta Neuropathol; 2018 Aug; 136(2):211-226. PubMed ID: 29909548
[TBL] [Abstract][Full Text] [Related]
7. Significance of molecular classification of ependymomas: C11orf95-RELA fusion-negative supratentorial ependymomas are a heterogeneous group of tumors.
Fukuoka K; Kanemura Y; Shofuda T; Fukushima S; Yamashita S; Narushima D; Kato M; Honda-Kitahara M; Ichikawa H; Kohno T; Sasaki A; Hirato J; Hirose T; Komori T; Satomi K; Yoshida A; Yamasaki K; Nakano Y; Takada A; Nakamura T; Takami H; Matsushita Y; Suzuki T; Nakamura H; Makino K; Sonoda Y; Saito R; Tominaga T; Matsusaka Y; Kobayashi K; Nagane M; Furuta T; Nakada M; Narita Y; Hirose Y; Ohba S; Wada A; Shimizu K; Kurozumi K; Date I; Fukai J; Miyairi Y; Kagawa N; Kawamura A; Yoshida M; Nishida N; Wataya T; Yamaoka M; Tsuyuguchi N; Uda T; Takahashi M; Nakano Y; Akai T; Izumoto S; Nonaka M; Yoshifuji K; Kodama Y; Mano M; Ozawa T; Ramaswamy V; Taylor MD; Ushijima T; Shibui S; Yamasaki M; Arai H; Sakamoto H; Nishikawa R; Ichimura K;
Acta Neuropathol Commun; 2018 Dec; 6(1):134. PubMed ID: 30514397
[TBL] [Abstract][Full Text] [Related]
8. EZHIP: a new piece of the puzzle towards understanding pediatric posterior fossa ependymoma.
Jenseit A; Camgöz A; Pfister SM; Kool M
Acta Neuropathol; 2022 Jan; 143(1):1-13. PubMed ID: 34762160
[TBL] [Abstract][Full Text] [Related]
9. Metabolic Regulation of the Epigenome Drives Lethal Infantile Ependymoma.
Michealraj KA; Kumar SA; Kim LJY; Cavalli FMG; Przelicki D; Wojcik JB; Delaidelli A; Bajic A; Saulnier O; MacLeod G; Vellanki RN; Vladoiu MC; Guilhamon P; Ong W; Lee JJY; Jiang Y; Holgado BL; Rasnitsyn A; Malik AA; Tsai R; Richman CM; Juraschka K; Haapasalo J; Wang EY; De Antonellis P; Suzuki H; Farooq H; Balin P; Kharas K; Van Ommeren R; Sirbu O; Rastan A; Krumholtz SL; Ly M; Ahmadi M; Deblois G; Srikanthan D; Luu B; Loukides J; Wu X; Garzia L; Ramaswamy V; Kanshin E; Sánchez-Osuna M; El-Hamamy I; Coutinho FJ; Prinos P; Singh S; Donovan LK; Daniels C; Schramek D; Tyers M; Weiss S; Stein LD; Lupien M; Wouters BG; Garcia BA; Arrowsmith CH; Sorensen PH; Angers S; Jabado N; Dirks PB; Mack SC; Agnihotri S; Rich JN; Taylor MD
Cell; 2020 Jun; 181(6):1329-1345.e24. PubMed ID: 32445698
[TBL] [Abstract][Full Text] [Related]
10. Chromosome 1q gain and tenascin-C expression are candidate markers to define different risk groups in pediatric posterior fossa ependymoma.
Araki A; Chocholous M; Gojo J; Dorfer C; Czech T; Heinzl H; Dieckmann K; Ambros IM; Ambros PF; Slavc I; Haberler C
Acta Neuropathol Commun; 2016 Aug; 4(1):88. PubMed ID: 27550150
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of chromosome 1q gain in intracranial ependymomas.
Rajeshwari M; Sharma MC; Kakkar A; Nambirajan A; Suri V; Sarkar C; Singh M; Saran RK; Gupta RK
J Neurooncol; 2016 Apr; 127(2):271-8. PubMed ID: 26725097
[TBL] [Abstract][Full Text] [Related]
12. EZHIP/CXorf67 mimics K27M mutated oncohistones and functions as an intrinsic inhibitor of PRC2 function in aggressive posterior fossa ependymoma.
Hübner JM; Müller T; Papageorgiou DN; Mauermann M; Krijgsveld J; Russell RB; Ellison DW; Pfister SM; Pajtler KW; Kool M
Neuro Oncol; 2019 Jul; 21(7):878-889. PubMed ID: 30923826
[TBL] [Abstract][Full Text] [Related]
13. Current and evolving knowledge of prognostic factors for pediatric ependymomas.
Andreiuolo F; Ferreira C; Puget S; Grill J
Future Oncol; 2013 Feb; 9(2):183-91. PubMed ID: 23414469
[TBL] [Abstract][Full Text] [Related]
14. Recent perspectives of ependymomas (childhood brain tumors).
Zeng ZD; Liu FL; Li SX
Eur Rev Med Pharmacol Sci; 2017 Oct; 21(4 Suppl):13-19. PubMed ID: 29165771
[TBL] [Abstract][Full Text] [Related]
15. Targeting integrated epigenetic and metabolic pathways in lethal childhood PFA ependymomas.
Panwalkar P; Tamrazi B; Dang D; Chung C; Sweha S; Natarajan SK; Pun M; Bayliss J; Ogrodzinski MP; Pratt D; Mullan B; Hawes D; Yang F; Lu C; Sabari BR; Achreja A; Heon J; Animasahun O; Cieslik M; Dunham C; Yip S; Hukin J; Phillips JJ; Bornhorst M; Griesinger AM; Donson AM; Foreman NK; Garton HJL; Heth J; Muraszko K; Nazarian J; Koschmann C; Jiang L; Filbin MG; Nagrath D; Kool M; Korshunov A; Pfister SM; Gilbertson RJ; Allis CD; Chinnaiyan AM; Lunt SY; Blüml S; Judkins AR; Venneti S
Sci Transl Med; 2021 Oct; 13(614):eabc0497. PubMed ID: 34613815
[TBL] [Abstract][Full Text] [Related]
16. Molecular genetics of ependymomas and pediatric diffuse gliomas: a short review.
Nobusawa S; Hirato J; Yokoo H
Brain Tumor Pathol; 2014 Oct; 31(4):229-33. PubMed ID: 25182241
[TBL] [Abstract][Full Text] [Related]
17. TERT promoter mutation and chromosome 6 loss define a high-risk subtype of ependymoma evolving from posterior fossa subependymoma.
Thomas C; Thierfelder F; Träger M; Soschinski P; Müther M; Edelmann D; Förster A; Geiler C; Kim HY; Filipski K; Harter PN; Schittenhelm J; Eckert F; Ntoulias G; May SA; Stummer W; Onken J; Vajkoczy P; Schüller U; Heppner FL; Capper D; Koch A; Kaul D; Paulus W; Hasselblatt M; Schweizer L
Acta Neuropathol; 2021 Jun; 141(6):959-970. PubMed ID: 33755803
[TBL] [Abstract][Full Text] [Related]
18. Epigenomic analysis of Alu repeats in human ependymomas.
Xie H; Wang M; Bonaldo Mde F; Rajaram V; Stellpflug W; Smith C; Arndt K; Goldman S; Tomita T; Soares MB
Proc Natl Acad Sci U S A; 2010 Apr; 107(15):6952-7. PubMed ID: 20351280
[TBL] [Abstract][Full Text] [Related]
19. Diagnostics of pediatric supratentorial RELA ependymomas: integration of information from histopathology, genetics, DNA methylation and imaging.
Pagès M; Pajtler KW; Puget S; Castel D; Boddaert N; Tauziède-Espariat A; Picot S; Debily MA; Kool M; Capper D; Sainte-Rose C; Chrétien F; Pfister SM; Pietsch T; Grill J; Varlet P; Andreiuolo F
Brain Pathol; 2019 May; 29(3):325-335. PubMed ID: 30325077
[TBL] [Abstract][Full Text] [Related]
20. Epigenomic alterations define lethal CIMP-positive ependymomas of infancy.
Mack SC; Witt H; Piro RM; Gu L; Zuyderduyn S; Stütz AM; Wang X; Gallo M; Garzia L; Zayne K; Zhang X; Ramaswamy V; Jäger N; Jones DT; Sill M; Pugh TJ; Ryzhova M; Wani KM; Shih DJ; Head R; Remke M; Bailey SD; Zichner T; Faria CC; Barszczyk M; Stark S; Seker-Cin H; Hutter S; Johann P; Bender S; Hovestadt V; Tzaridis T; Dubuc AM; Northcott PA; Peacock J; Bertrand KC; Agnihotri S; Cavalli FM; Clarke I; Nethery-Brokx K; Creasy CL; Verma SK; Koster J; Wu X; Yao Y; Milde T; Sin-Chan P; Zuccaro J; Lau L; Pereira S; Castelo-Branco P; Hirst M; Marra MA; Roberts SS; Fults D; Massimi L; Cho YJ; Van Meter T; Grajkowska W; Lach B; Kulozik AE; von Deimling A; Witt O; Scherer SW; Fan X; Muraszko KM; Kool M; Pomeroy SL; Gupta N; Phillips J; Huang A; Tabori U; Hawkins C; Malkin D; Kongkham PN; Weiss WA; Jabado N; Rutka JT; Bouffet E; Korbel JO; Lupien M; Aldape KD; Bader GD; Eils R; Lichter P; Dirks PB; Pfister SM; Korshunov A; Taylor MD
Nature; 2014 Feb; 506(7489):445-50. PubMed ID: 24553142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
